Actinium Pharmaceuticals (ATNM) Q2 2024 earnings summary

Executive summary

• Actinium Pharmaceuticals focuses on developing Antibody Radiation Conjugates (ARCs) and targeted radiotherapies for relapsed or refractory cancers, with lead candidates Iomab-B and Actimab-A in advanced clinical stages.

• The company is advancing a pipeline targeting high unmet needs in hematology and oncology, leveraging a robust IP portfolio and manufacturing expertise.

• Iomab-B's U.S. regulatory pathway faces a setback as the FDA requires an additional clinical trial to demonstrate overall survival benefit, despite positive SIERRA trial results.

• Actimab-A is being developed in collaboration with the NCI, with preclinical and clinical data supporting its potential in AML and other indications.

• The company maintains strong cash reserves and expects to fund operations for more than 12 months.

Financial highlights

• Net loss for Q2 2024 was $11.4 million, a decrease from $15.2 million in Q2 2023, driven by lower R&D and G&A expenses and higher interest income.

• Net loss for the six months ended June 30, 2024 was $20.0 million, down from $26.2 million for the same period in 2023.

• Research and development expenses for Q2 2024 were $8.8 million, down from $11.1 million in Q2 2023, mainly due to lower CMC activity for Iomab-B.

• General and administrative expenses for Q2 2024 were $3.6 million, down from $4.6 million in Q2 2023.

• Cash and cash equivalents as of June 30, 2024 were $86.0 million, up from $76.7 million at year-end 2023, reflecting net proceeds from stock sales.

Outlook and guidance

• Existing resources are expected to fund planned operations for more than 12 months from the report date.

• The company plans to seek a strategic partner for Iomab-B in the U.S. after further FDA discussions and will continue to advance its pipeline and preclinical programs.